

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁴ : C12N 05/00, 05/02	A1	(11) International Publication Number: WO 89/ 03875
		(43) International Publication Date: 5 May 1989 (05.05.89)
(21) International Application Number: PCT/US88/03740 (22) International Filing Date: 24 October 1988 (24.10.88)	(74) Agent: JOHNSON, Philip, S.; Woodcock Washburn Kurtz Mackiewicz & Norris, One Liberty Place, 46th Floor, Philadelphia, PA 19103 (US).	
(31) Priority Application Number: 114,242	(81) Designated States: AU, BR, DE, DK, FI, JP, KR, NL, NO, SE.	
(32) Priority Date: 28 October 1987 (28.10.87)	Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(33) Priority Country: US		
(71) Applicant: THOMAS JEFFERSON UNIVERSITY [US/US]; 11th and Walnut Streets, Philadelphia, PA 19107 (US).		
(72) Inventors: CARABASI, R., Anthony ; 818 Northwinds Drive, Bryn Mawr, PA 19010 (US). JARRELL, Bruce, E. ; 8101 St. Martins Lane, Philadelphia, PA 19118 (US). WILLIAMS, Stuart, K. ; 103 Cambridge Drive, Wilmington, DE 19803 (US).		
(54) Title: METHOD OF REENDOTHELIALIZING VASCULAR LININGS		
<p>(57) Abstract</p> <p>A method for treating the vascular passage of a patient, damaged by procedures such as an endarterectomy which denude portions of the vascular passages of their endothelial cell linings, is disclosed. In this method, endothelial cells are isolated from the patient's own microvessels, the flow of blood through the patient's damaged vascular passage is interrupted, the endothelial cells isolated from the patient's microvessels are applied to the surface of the denuded portion of the patient's vascular passage in a density sufficient to provide coverage of at least about 50 % of said denuded portion, and interruption of blood flow through the vascular passage is maintained for a period of time sufficient to allow the seeded cells to form an attachment to the vascular lining sufficient to withstand the shear created by resumed blood flow through the vascular passage.</p>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	ML	Mali
AU	Australia	GA	Gabon	MR	Mauritania
BB	Barbados	GB	United Kingdom	MW	Malawi
BE	Belgium	HU	Hungary	NL	Netherlands
BG	Bulgaria	IT	Italy	NO	Norway
BJ	Benin	JP	Japan	RO	Romania
BR	Brazil	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	LI	Liechtenstein	SN	Senegal
CH	Switzerland	LK	Sri Lanka	SU	Soviet Union
CM	Cameroon	LU	Luxembourg	TD	Chad
DE	Germany, Federal Republic of	MC	Monaco	TG	Togo
DK	Denmark	MG	Madagascar	US	United States of America
FI	Finland				

- 1 -

METHOD OF REENDOTHELIALIZING VASCULAR LININGSBACKGROUND OF THE INVENTIONFIELD OF THE INVENTION

This invention relates to a method of reendothelializing the vascular passage of a patient, the lining of which has been substantially denuded of endothelial cells by virtue, for example, of procedures such as endarterectomy.

RELATED APPLICATIONS

USSN 742,086, filed June 6, 1985, by Williams and Jarrell, discloses a method for treating a synthetic or naturally occurring implant intended for implantation in a human patient comprising the steps of obtaining human microvascular endothelial cell rich tissue from that patient, separating microvascular endothelial cells from that tissue; and applying said microvascular endothelial cells onto said implant to provide at least about 50% or greater confluence of said cells on the surface of said implant to be treated.

USSN 848,453, filed on April 4, 1986 as a continuation-in-part of USSN 742,086, discloses a method of treating an implant intended for implantation in a human patient, comprising the steps of providing a synthetic substrate material and treating that material with Type IV/V collagen to improve human endothelial cell adhesion, proliferation and morphology. In the preferred embodiment, the endothelial cells are derived from the endothelial cell rich tissue of the patient undergoing implantation.

USSN 927,745, filed by Jarrell and Williams on November 6, 1986, discloses a method of determining endothelial cell coverage on a prosthetic surface.

The disclosures of these three applications are hereby incorporated by reference.

- 2 -

DESCRIPTION OF THE ART

Atherosclerotic vascular disease remains the leading cause of death among Americans. As medical science has become more sophisticated, increasing use of invasive
5 vascular procedures are being applied to obstructed vessels in the absence of effective preventive or therapeutic drug modalities. For example, the use of arterial endarterectomy as well as percutaneous balloon dilatation of vessels for pathologic stenosis have become routine
10 hospital procedures. Although these and other procedures are often successful, a common complication after the procedures is the occurrence of vessel wall abnormalities. These abnormalities include recurrent stenosis due to atherosclerosis, smooth muscle proliferation, loss of
15 vessel wall integrity as a result of fibrosis and thrombosis of the vessel. Injury to or removal of the endothelial cells lining the blood vessels is one of several common denominators inherent to vascular procedures, and current data suggest that spontaneous
20 reendothelialization of these injuries may occur slowly, partially, or not at all.

The endothelial lining of blood vessels is a highly complex, multi-functional cell surface. These cells interact with both the blood and the underlying vessel wall
25 components to maintain a physiological homeostasis. The effects of endothelial injury have been studied in several experimental models mostly designed to study the development of biological mechanisms. After endothelial injury, the vessel wall loses its non-thrombogenic
30 properties. One of the first events to occur is platelet adherence to the vessel surface, which is extensive over the first several days but diminishes over the following week. Steele, P., Chesebro, J., Stanson, A., Holmes, D., Dewanjee, M., Badimon, L., Fuster, V., Circ. Res., 57, No.
35 1:105-112 (1985). Platelets adhere to the subendothelium and undergo a release reaction, inducing further activation of the plasma coagulation system. Osterud, B. et al., J. Proc. Natl. Acad. Sci. U.S.A., 74, p. 5260 (1977). One of

- 3 -

the released products is platelet derived growth factor (PDGF), which is mitogenic for vascular smooth muscle cells grown in tissue culture. It has been postulated that local release of this factor may play a role in the genesis of

5 intimal hyperplasia and atherosclerosis. Harker, L. et al., J. Clin. Invest., 58, 731 (1976); Friedman, R. et al., J. Clin. Invest., 60, 1191 (1977). Other substances released from platelets include heparitinase and platelet factor 4. The latter protein has high affinity for heparin

10 and has been shown to penetrate into the vascular media after de-endothelialization. Goldgerg, J.D. et al., J. Science, 209, 611 (1980). Macrophages, which are also a rich source of SMC mitogens, are frequently present in the injured area. Gimbrone, M.A. Jr., In: Jaffe, E.A., Editor,

15 Biology of Endothelial Cells, Martinus Nijhoff Publishers, pp. 97-107 (1984). The final response of the injured arterial wall, independent of whether the injury is chemical, mechanical or biological, is characterized by proliferation of cells in the intima to form a fibro-

20 musculo-elastic plaque. Hoff, H., Thromb. Haemostas., 40, 121 (1970).

Clearly, the endothelial cell plays a key role in the etiology of blood vessel dysfunction. It is anticipated that restoration of intact endothelium

25 immediately following injury might reduce or alter the events occurring immediately after injury. Therefore, it is an object of this invention to provide a method for reendothelializing the linings of vascular passages which have been substantially denuded of endothelial cells.

30 Recent years have seen refinements made in the isolation of endothelial cells (EC) and their growth in culture. The addition of endothelial cell growth factor (ECFG) and heparin to culture medium has allowed human adult large vessel EC to remain in culture for greater than

35 50 population doublings. Jaffe, E.A. et al., J. Clin. Invest., 52:2745 (1973); Maciag, T., et al., J. Cell Biol., 91:420 (1981); Thornton, S.C. et al., Science, 222:623-624 (1983); Jarrell, B.E., et al., J. Vasc. Surg., 1:757-764

- 4 -

(1984). Human microvessel EC have also been routinely isolated in large quantities using collagenase digestion and Percoll gradient purification followed by long term cultivation in heparin - ECFG supplemented medium.

- 5 Jarrell, B.E. et al., Surgery, Vol. 100, No. 2, pp. 392-399 (August 1986).

These advances in EC isolation and culture have been used to better understand the interactions between these EC and prosthetic vascular grafts. Watkins, M.T. et al., J. Surg. Res., 36:588-596 (1984); Williams, S.K. et al., J. Surg. Res., 38:618-629 (1985); Baker, K.S. et al., Am. J. Surg., 150:197-200 (1985). In these studies it has been noted that human EC possess the ability to firmly adhere to both plasma coated surfaces and human amnion type
15 IV/V collagen after a ten to thirty minute incubation period. Jarrell, B.E. et al., Ann. Surg., Vol. 203, No. 6, pp. 671 - 678 (June 1986). Another observation was that freshly isolated human microvessel EC obtained from fat
20 tissue also possessed this property and could be isolated in quantities of 10^6 EC per gram of fat. Radomski, J., et al., J. Surg. Res., 42, 133-140 (1987); Jarrell, B.E. et al., Surgery, Vol. 100, No. 2, pp. 392-399 (August 1986).

At least one study has examined the utility of treating the neointimal hyperplasia developed after
25 endarterectomy of a normal artery by endothelial cell sodding. Bush, Jr., Harry L., Jakubowski, Joseph A., Sentissi, Joanna M., Curl, Richard G., Hayes, John A., and Deykin, Daniel, "Neointimal Hyperplasia Occurring After Carotid Endarterectomy in a Canine Model: Effect of
30 Endothelial Cell Seeding vs. Perioperative Aspirin," Journal of Vascular Surgery, Vol. 3, No. 1, pp. 118-125 (January 1987). In this study, endothelial cells were harvested from the veins of dogs selected to undergo treatment. The cells were suspended in sterile autogenous
35 serum, and this suspension was injected into the endarterectomized segment of the dog's artery. From this work, the authors concluded that sodding the

- 5 -

endarterectomized surface with autogenous endothelial cells did minimize proliferative lesion in the artery.

SUMMARY OF THE INVENTION

This invention relates to a method of
5 reendothelializing the vascular passage of a patient, the lining of which has been substantially denuded of endothelial cells, using that patient's own endothelial cells. In this method, endothelial cells are isolated from the patient's own microvessels, the flow of blood through
10 the patient's damaged vascular passage is interrupted, the endothelial cells isolated from the patient's microvessels are applied to the surface of the denuded portion of the patient's vascular passage in a density sufficient to provide coverage of at least about 50% of said denuded
15 portion, and interruption of blood flow through the vascular passage is maintained for a period of time sufficient to allow the cells to form an attachment to the vascular lining sufficient to withstand the shear created by resumed blood flow through the vascular passage.

DETAILED DESCRIPTION OF THE INVENTION

20 The patients who may benefit from the method of this invention are those who have been subjected to procedures which damage the endothelial cell linings of the vascular passages, e.g., percutaneous transluminal
25 angioplasty. By "substantially denuded of endothelial cells", as that phrase is used herein, we mean a vascular passage the endothelial cell lining of which has been injured or removed to an extent likely to cause adverse side-effects to the patient. Such injuries can be
30 classified as level I, II or III injuries, level I injury being one that exposes principally basement membrane, level II injury being one that exposes primarily sub-basement membrane, interstitial collagen and the internal elastic lamina, and a level III injury being one that exposes the
35 deeper layers including the media and smooth muscle cells in areas of internal elastic lamina fracture.

Endothelial cells for use in the method of this invention are preferably obtained from the patient

- 6 -

undergoing the vascular treatment; however, it should be possible to obtain human perinephric fat from brain-dead but heart-beating cadaver donors or from donors other than the patient during the donor's surgery. Microvascular
5 endothelial cells, that is, cells which are derived from capillaries, arterioles and venules, will function suitably in place of large vessel cells even though there are morphological and functional differences between large
10 vessel endothelial cells and microvascular endothelial cells in their native tissues. Microvascular endothelial cells are present in an abundant supply in body tissue, and are therefore the preferred source of endothelial cells for use in this invention. Although endothelial cells may be isolated from tissues such as brain, lung, retina, adrenal
15 glands, liver and muscle tissue, the use of fat tissue as the source for the cells is preferred due to its abundance and availability, and due to the fact that its removal should not adversely affect the patient being treated.

To obtain microvascular endothelial cells from
20 the patient, the source tissue, such as fat tissue, is removed from the patient after sterile conditions have been established. Microvascular endothelial cells in that fat tissue are then quickly separated from their related tissue by enzymatic digestion and centrifugation and may be used
25 to treat the surface of the damaged vascular linings of the patient during the latter stages of the same operation. This procedure obviates any need to culture adult endothelial cells to increase their numbers, and permits a patient to receive treatment with his own fresh, "healthy"
30 endothelial cells.

The procedure useful for isolating large quantities of endothelial cells without the need for tissue culturing may be readily performed in an operating room and is described in its preferred embodiment in greater detail
35 as follows. The fat tissue retrieved from the patient or donated from another source is immediately transferred to ice cold buffered saline (pH 7.4) wherein the buffering agent is preferably a phosphate, i.e., a phosphate buffered

- 7 -

saline (PBS). The tissue is minced with fine scissors and the buffer decanted. Alternatively, fat tissue obtained by liposuction may be used as the source of endothelial cells. The proteolytic enzyme collagenase, containing caseanase and trypsin, is added to the tissue and incubated at 37°C until the tissue mass disperses. This digestion occurs within thirty minutes and generally should occur in less than twenty minutes. The digest is transferred to a sterile test tube and centrifuged at low speed (700 x g) in a table top centrifuge for five minutes at room temperature. The pellet of cells thus formed consists of greater than ninety-five percent (95%) endothelial cells. These endothelial cells are described herein as microvascular endothelial cells since they originate from the arterioles, capillaries and venules, all elements of the microvasculature. This microvascular endothelial cell pellet is washed one time by centrifugation with a buffer and can be used directly without further purification for application to the injured vascular lining of the patient. Suitable buffers include buffered saline such as PBS as well as intravenous infusion solutions and peritoneal dialysis solutions.

Alternatively, the microvascular endothelial cells may be further purified by centrifuging the cells with a continuous gradient. This gradient can be formed from a number of large molecular weight solutes, including albumin, dextran, or commercially available density gradient materials, such as Percoll (Pharmacia Inc., Piscataway, N.J.) or Nycodenz (Nyegaard and Company, Norway). Gradient centrifugation is used to remove red cells, white cells and smooth muscle cells. A forty-five percent (45%) solution of Percoll has routinely been used in the studies reported herein. Cells are layered on the surface of the Percoll solution and centrifuged at 13,000 x g for twenty minutes. Alternatively, cells are layered on a preformed Percoll gradient and centrifuged at 400 x g for five minutes at room temperature. A thick band of endothelial cells results at the upper end of the gradient.

- 8 -

These cells are removed with a pipette and washed one time by centrifugation with phosphate-buffered saline.

The endothelial cells isolated as described above may be used directly to treat the injured vascular lining of the patient. They may be mixed with blood or plasma and used to seed the surface of the patient's vascular lining or may be mixed with a non-clotting medium such as a buffered saline and used to sod the surface. The term "seeding" as it is used herein refers to the procedure which entails mixing cells with a matrix followed by placement of that mixture onto the surface to be seeded, e.g., the vascular lining. The matrix may be any gel or clot-forming substance, such as blood or plasma, that may be used as a vehicle in which to suspend and trap the cells. This endothelial cell-matrix mixture adheres to the surface and gels, "trapping" the cells within the matrix until they are able to multiply and grow out over the surface. The term "sodding", on the other hand, is used herein to refer to the procedure which entails mixing cells in a simple medium such as a buffer solution that does not gel under the ambient conditions of the sodding procedure (e.g., a temperature of from about body temperature to about 37°C) and applying that mixture to cover a surface. In the sodding process, cells approach the surface to be treated due to gravity and attach directly to the surface, rather than being "trapped" within a portion of the mixture as in the seeding process.

In a preferred embodiment, the cells are pelletized by centrifugation (200 x g) and the pellet is then resuspended with protein-containing buffer solution. This resuspension should be performed at a ratio of approximately 1:5 to 1:15 or, preferably, about 1:10 volumes of packed microvascular endothelial cells to buffer solution. This resuspension may then be used to sod the lining of the injured vascular passageway. Prior to sodding, certain agents may be added to the suspension in an effort to aid cell adhesion and spreading, including fibronectin, platelet poor plasma, albumin, Dextran 40 or

- 9 -

Dextran 70, endothelial cell growth factor and heparin sulfate.

The goal in this procedure, of course, is to create a confluent layer of endothelial cells on the vascular surface, or to restore the vascular surface to its pre-injury, "healthy" state. To achieve this goal, the initial adherence of cells to the vascular lining surface should preferably be sufficient to provide at least about fifty percent (50%) initial surface coverage. Application at fifty percent (50%) confluence requires the cells to duplicate one time to create a confluent cell layer. Since, as discussed below, it will be necessary to restrict the flow of blood through the vascular passageway during the seeding or sodding process, since such flow restriction should be maintained for as short a time as possible for the benefit of the patient, and since resumed blood flow through the passageway may hinder cell duplication, it is obviously desirable to apply as many endothelial cells to the vascular lining surface as possible. Most preferably, the cells are seeded or sodded onto the vascular lining surface at a density equivalent to confluence, i.e., greater than about 10^5 cells per cm^2 surface area. It is necessary to interrupt or reduce the flow of blood through the vascular passageway during the time of seeding or sodding for a period of time sufficient to permit adhesion of the cells to the lining of that passageway. More preferably, flow is interrupted or reduced for a period of time sufficient for adhesion of a confluent monolayer of cells. For certain arteries, it may be necessary to use a temporary shunt around the affected portion to sufficiently reduce blood flow. In other situations, the artery may simply be clamped or constricted upstream to accomplish the necessary flow reduction. It is preferable, especially in the sodding procedure, to apply pressure to force the cells against the vessel wall. It is believed that the optimal temperature for inducing attachment of the cells to the vessel wall is about 37°C . Once the endothelial cells have established an attachment sufficient to withstand the shear

- 10 -

created by the blood flow through the vascular passageway, flow may be reestablished therethrough, whereupon the previously denuded portion of the passageway will be protected by a "natural" antithrombogenic surface.

5 Studies on human basement membrane surfaces obtained from amnion have suggested that type IV/V collagen exhibits properties which support rapid adherence and spreading of endothelial cells after sodding. Conversely, human plasma derived clot and human type I/III interstitial
10 collagen have been found to support less rapid cell spreading when examined under similar conditions. An injured vessel will most likely expose collagen I/III smooth muscle cells or become coated with plasma proteins, providing a suboptimal surface for endothelial cell
15 attachment and spreading. Pre-treatment of the residual injured vessel wall may enhance adherence and spreading qualities and allow a more satisfactory surface to form. Thus, the vessel wall may be pre-treated with one or more of the following:

20 fibronectin
 laminin
 plasma, prepared with EDTA and clotted onto
surface
 solubilized collagen IV/V
25 platelets
 red blood cells
 Dextran 40 or Dextran 70
 heparin sulfate
 endothelial cell growth factor
30 serum
 serum albumin
 thrombospondin
 heparan
 heparan sulfate

- 11 -

I CLAIMED AS MY INVENTION:

1. A method of reendothelializing the vascular passage of a patient, the lining of which has been substantially denuded of endothelial cells, comprising

5 (a) interrupting the flow of blood through said vascular passage,

(b) applying to said denuded vascular lining endothelial cells retrieved from the microvessels of said patient in a density sufficient to provide coverage of at least about 50% of said denuded portion; and

10 (c) maintaining the interruption of blood flow through said vascular passage for a period of time sufficient to allow said applied cells to form an attachment to said vascular lining sufficient to withstand the shear created by resumed blood flow through said

15 vascular passage.

2. The method of Claim 1 where said endothelial cells are applied in a density of at least about 1×10^5 cells per cm^2 of seeded surface.

20 3. The method of Claim 1 where said endothelial cells are applied in a density sufficient to form a confluent layer of said cells on said vascular lining.

4. The method of Claim 1 where said endothelial cells are applied to said vascular passage in a suspension

25 of blood or plasma.

5. The method of Claim 2 where said endothelial cells are applied to said vascular passage in a suspension of blood or plasma.

6. The method of Claim 3 where said endothelial

30 cells are applied to said vascular passage in a suspension of blood or plasma.

- 12 -

7. The method of Claim 1 where said endothelial cells are applied to said vascular passage in a suspension of a non-gel-forming buffer solution.

8. The method of Claim 2 where said endothelial cells are applied to said vascular passage in a suspension of a non-gel-forming buffer solution.

9. The method of Claim 3 where said endothelial cells are applied to said vascular passage in a suspension of a non-gel-forming buffer solution.

10. The method of Claim 1 where said endothelial cells are derived from the fat tissues of the patient.


11. The method of Claim 4 where said endothelial cells are derived from the fat tissues of the patient.

12. The method of Claim 7 where said endothelial cells are derived from the fat tissues of the patient.

13. The method of Claim 1 where said endothelial cells are retrieved from said patient and applied to said patient's vascular lining during the same operative procedure.

INTERNATIONAL SEARCH REPORT

International Application No. **PCT/US88/03740**

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ⁶		
According to International Patent Classification (IPC) or to both National Classification and IPC		
IPC(4): C12N 05/00; C12N 05/02		
U.S. CL.: 435/240.2; 435/240.25		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁷		
Classification System	Classification Symbols	
U.S.	435/240.2, 240.25	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸		
Computer Searched CAS (1967-1988) Biosis (1969-1988), APS(1975-1988) Search terms: endothelialize or reendothelialize, vascular arteries, veins or capillaries.		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ⁹		
Category [*]	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	Williams, S. "Isolation and Culture of Microvessel and Large-Vessel Endothelial Cells: Their Use in Transport and Clinical Studies", in <u>Microvascular Perfusion and Transport in Health and Disease</u> , edited by McDonagh. Published by Karger, Basel Switzerland 1947. See Chapter 8.	1-13
Y	JOURNAL OF VASCULAR SURGERY, Vol. 1 1984, St. Louis, MO, USA, Jarrell et al. "Human Adult Endothelial Cell Growth in Culture". pages 757-764.	1-13
<p>[*] Special categories of cited documents: ¹⁰</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search	Date of Mailing of this International Search Report	
04 January 1989	07 MAR 1989	
International Searching Authority	Signature of Authorized Officer	
ISA/US	 LORI Y. BEARDELL	